Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.63 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.63 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.63 |
| ▸ | TNF | P01375 | 2/20 | 0.63 |
| ▸ | IL1B | P01584 | 2/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21671748 | 1.00 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671750 | 0.80 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671743 | 0.80 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671648 | 0.80 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671749 | 0.80 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671664 | 0.80 | CRBN (0.72) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671772 | 0.80 | CRBN (0.72) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671649 | 0.80 | CRBN (0.72) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL26671992 | 0.78 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671630 | 0.78 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2023-07-18 | — | — | US | disclosed |
| US-20210206743-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| US-11001566-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2021-05-11 | — | — | US | disclosed |
| US-20200039950-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFORE, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | KANGPU BIOPHARMACEUTICALS, LTD (CN) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206743-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | CYP4F11, WEE1, CYP51A1 | CRBN 4188/4885DDB1 4571/4885IKZF3 670/4885 |
| US-11001566-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | CRBN 4188/4885DDB1 4571/4885IKZF3 670/4885 |
| US-20200039950-A1 | QUINAZOLINONE DERIVATIVE, PREPARATION METHOD THEREFORE, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | CYP2F1, CYP2C19, CYP4F3 | CRBN 4087/4885DDB1 3823/4885IKZF3 801/4885 |
| US-11702399-B2 | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | CYP4F11, WEE1, CYP51A1 | CRBN 4188/4885DDB1 4571/4885IKZF3 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.